Pariwar
About
What industry does Pariwar operate in?
Pariwar operates in HealthTech, MedTech, Fertility Tech, Personalized Health, AI-Driven Health, Consumer App.
What is Pariwar's current status?
Pariwar's current operating status is: Inactive.
Evidence-based weekly meal plans, photo, voice and barcode food logging, unlimited dietitian-grade coach chat, and step-by-step cooking videos. 7-day free trial, then A$27.99/month.
Nidl provides an AI agent workforce for Canadian paramedical and dental clinics, automating administrative tasks like calls, scheduling, and billing.
Pammela is an AI layer for EHR systems, designed to assist clinics and mental health practices by automating clinical note generation and improving efficiency.
Building a mental health app focused on emotional well-being and self-care.
An open standard for AI-native business software, offering four elements, a manifesto, and no license gate.
Developing AI-informed, expert-driven clinical decision support tools for aphasia rehabilitation.
AI precision medicine company transforming cancer diagnostics and patient outcomes through cutting-edge foundation models and multi-modal data.
An AI copilot for doctors that provides immediate, evidence-based answers to clinical questions from peer-reviewed medical sources.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 34 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Scan this site yourselfGoogle PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.
Open in PageSpeed InsightsStar ratings come from visitors, one per person per profile, and are shown exactly as given: we do not weight, curate or filter them. Reviews are published in full alongside the rating that accompanied them.
No comments yet. Be the first to share your take.